14 results on '"Aigret, Benoit"'
Search Results
2. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
- Author
-
Bagewadi, Abhay, Patrick, Abigail, Shenoy, Achuth, Redmond, Aisling, Muddu, Ajay, Northrop, Alex, Groves, Alice, Shiner, Alice, Heer, Amardeep, Takhar, Amrit, Bowles, Amy, Jarman, Andrea, Wong, Angela, Lucas, Angie, Gibbons, Anita, Dhar, Anjan, Curry, Anji, Lalonde, Anna, Swinburn, Anna, Turner, Anne, Lydon, Anne-Marie, Gunstone, Anthony, Lee, Arlene, Nambi, Arul, Ariyarathenam, Arun, Elden, Ashley, Wilson, Ashley, Donepudi, Balaji, Campbell, Barbara, Uszycka, Basia, Bowers, Ben, Coghill, Ben, de Quadros, Bruno, Cheah, Calvin, Bratten, Carla, Brown, Carly, Moorbey, Chantelle, Clisby, Charles, Gordon, Charles, Schramm, Chris, Castle, Chris, Newark, Chris, Norris, Chrissie, A'Court, Christine, Graham, Claire, Fletcher, Clare, Grocott, Clare, Rees, Colin, Bakker, Corinne, Paschalides, Costas, Vickery, Craig, Schembri, Damian, Morris, Danielle, Hagan, Daryl, Cronk, David, Goddard, David, Graham, David, Phillips, Dean, Prabhu, Deeksha, Kejariwal, Deepak, Garg, Dhirendra, Lonsdale, Diane, Butterworth, Dianne, Clements, Donna, Bradman, Drew, Blake, Duncan, Mather, Elizabeth, O'Farrell, Ewan, Markowetz, Florian, Adams, Fran, Pesola, Francesca, Forbes, Gareth, Taylor, Gary, Collins, Glenn, Irvine, Gordon, Fourie, Gysbert, Doyle, Harriet, Barnes, Heather, Bowyer, Helen, Whiting, Helen, Beales, Ian, Binnian, Ian, Bremner, Ian, Jennings, Ian, Troiceanu, Ilona, Modelell, Ines, Emmerson, Ingrid, Ortiz, Jacobo, Lilley, Jacqueline, Harvey, Jacquelyn, Vicars, Jacqui, Takhar, Jagjit, Larcombe, James, Bornschein, Jan, Aldegather, Jehad, Johnson, Jenny, Ducker, Jill, Skinner, Jo, Dash, Joanne, Walsh, Joanne, Miralles, Jose, Ridgway, Josephine, Ince, Julia, Kennedy, Julie, Hampson, Kat, Milne, Kate, Ellerby, Katherine, Priddis, Katherine, Rainsbury, Kathy, Powell, Kelly, Gunner, Kerry, Ragunath, Krish, Knox, Kyle, Baseley, Laura, White, Lauren, Lovat, Laurence, Berney, Lee, Crockett, Lindsay, Murray, Lisa, Westwood, Lisa, Chalkley, Lisa, Leggett, Loraine, Dale, Louise, Scovell, Louise, Brooks, Lucy, Saunders, Lucy, Owen, Lydia, Dilwershah, Maria, Baldry, Marie, Corcoran, Marie, Roy, Marie, Macedo, Mario, Attah, Mark, Anson, Mary-Jo, Rutter, Matt, Wallard, Matthew, Gaw, Matthew, Hunt, Matthew, Lea-Hagerty, Megan, Penacerrada, Melchizedek, Bianchi, Michele, Baker-Moffatt, Michelle, Czajkowski, Michelle, Sleeth, Michelle, Brewer, Nick, Wooding, Nick, Todd, Nicky, Millen, Nicola, Zolle, Olga, Whitehead, Orla, Ojechi, Patrick, Moore, Patrick, Banim, Paul, Spellar, Paula, Bhandari, Pradeep, Kant, Prashant, Nixon, Rachel, Russell, Rebecca, Roberts, Rebekah, Skule, Rene, West, Richard, Fox, Robin, Beesley, Ruth, Gibbins, Ruth, Osborne, Ruth, Thiagarajan, S, Bastiman, Sally, Warburton, Samantha, Pai, Samir, Leith-Russell, Sarah, Utting, Sarah, Watson, Sarah, Wytrykowski, Sarah, Singh, Satish, Malhotra, Shalini, Woods, Sharon, Conway, Shaun, Mateer, Sherrie, Macrae, Shona, Singh, Shruti, Fourie, Simona, Campbell, Siobhan, Parslow-Williams, Siobhan, Goel, Sonica, Dellar, Stephen, Jones, Stephen, Knight, Steve, Mackay-Thomas, Stuart, Mukherjee, Stuti, Allen, Sue, Henry, Suzanne, Evans, Tara, Leighton, Theresa, Bray, Tim, Shackleton, Tom, Santosh, Vanaja, Glover, Vicki, Chandraraj, Vijay, Elson, Will, Briggs, William, Barron, Zoe, Khan, Zohrah, Fitzgerald, Rebecca C, di Pietro, Massimiliano, O'Donovan, Maria, Maroni, Roberta, Muldrew, Beth, Debiram-Beecham, Irene, Gehrung, Marcel, Offman, Judith, Tripathi, Monika, Smith, Samuel G, Aigret, Benoit, Walter, Fiona M, Rubin, Greg, and Sasieni, Peter
- Published
- 2020
- Full Text
- View/download PDF
3. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study
- Author
-
Ross-Innes, Caryn S, Chettouh, Hamza, Achilleos, Achilleas, Galeano-Dalmau, Nuria, Debiram-Beecham, Irene, MacRae, Shona, Fessas, Petros, Walker, Elaine, Varghese, Sibu, Evan, Theodore, Lao-Sirieix, Pierre S, O'Donovan, Maria, Malhotra, Shalini, Novelli, Marco, Disep, Babett, Kaye, Phillip V, Lovat, Laurence B, Haidry, Rehan, Griffin, Michael, Ragunath, Krish, Bhandari, Pradeep, Haycock, Adam, Morris, Danielle, Attwood, Stephen, Dhar, Anjan, Rees, Colin, Rutter, Matt D, Ostler, Richard, Aigret, Benoit, Sasieni, Peter D, and Fitzgerald, Rebecca C
- Published
- 2017
- Full Text
- View/download PDF
4. Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux
- Author
-
Offman, Judith, Muldrew, Beth, O’Donovan, Maria, Debiram-Beecham, Irene, Pesola, Francesca, Kaimi, Irene, Smith, Samuel G., Wilson, Ashley, Khan, Zohrah, Lao-Sirieix, Pierre, Aigret, Benoit, Walter, Fiona M., Rubin, Greg, Morris, Steve, Jackson, Christopher, Sasieni, Peter, Fitzgerald, Rebecca C., and on behalf of the BEST3 Trial team
- Published
- 2018
- Full Text
- View/download PDF
5. Selective LC-MS/MS method for the identification of BMAA from its isomers in biological samples
- Author
-
Jiang, Liying, Aigret, Benoit, De Borggraeve, Wim M., Spacil, Zdenek, and Ilag, Leopold L.
- Published
- 2012
- Full Text
- View/download PDF
6. High-dose oral vitamin D supplementation and mortality in people aged 65 - 84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation
- Author
-
Rake, Christine, Gilham, Clare, Bukasa, Laurette, Ostler, Richard, Newton, Michelle, Peto Wild, James, Aigret, Benoit, Hill, Michael, Gillie, Oliver, Nazareth, Irwin, Sasieni, Peter, Martineau, Adrian, and Peto, Julian
- Abstract
Background: Randomised controlled trials demonstrating improved longevity are needed to justify high-dose vitamin D supplementation for older populations. Objectives: To demonstrate the feasibility of a large trial (n ≈ 20,000) of high-dose vitamin D in people aged 65–84 years through general practitioner (GP) practices, and to cluster randomise participating practices between open-label and double-blind randomisation to compare effects on recruitment, compliance and contamination. Design: Twenty GP practices were randomised in matched pairs between open-label and double-blind allocation. Within each practice, patients were individually randomised to vitamin D or control (i.e. no treatment or placebo). Participants were invited to attend their GP practice to provide a blood sample and complete a lifestyle questionnaire at recruitment and again at 2 years. Randomisation by telephone followed receipt of a serum corrected calcium assay confirming eligibility ( 400 IU vitamin D per day at 2 years was 5.0% in open practices and 4.8% in double-blind practices. Mean serum 25(OH)D concentration was 51.5 nmol/l [95% confidence interval (CI) 50.2 to 52.8 nmol/l] with 82.6% of participants
- Published
- 2020
7. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
- Author
-
Fitzgerald, Rebecca C, primary, di Pietro, Massimiliano, additional, O'Donovan, Maria, additional, Maroni, Roberta, additional, Muldrew, Beth, additional, Debiram-Beecham, Irene, additional, Gehrung, Marcel, additional, Offman, Judith, additional, Tripathi, Monika, additional, Smith, Samuel G, additional, Aigret, Benoit, additional, Walter, Fiona M, additional, Rubin, Greg, additional, Sasieni, Peter, additional, Bagewadi, Abhay, additional, Patrick, Abigail, additional, Shenoy, Achuth, additional, Redmond, Aisling, additional, Muddu, Ajay, additional, Northrop, Alex, additional, Groves, Alice, additional, Shiner, Alice, additional, Heer, Amardeep, additional, Takhar, Amrit, additional, Bowles, Amy, additional, Jarman, Andrea, additional, Wong, Angela, additional, Lucas, Angie, additional, Gibbons, Anita, additional, Dhar, Anjan, additional, Curry, Anji, additional, Lalonde, Anna, additional, Swinburn, Anna, additional, Turner, Anne, additional, Lydon, Anne-Marie, additional, Gunstone, Anthony, additional, Lee, Arlene, additional, Nambi, Arul, additional, Ariyarathenam, Arun, additional, Elden, Ashley, additional, Wilson, Ashley, additional, Donepudi, Balaji, additional, Campbell, Barbara, additional, Uszycka, Basia, additional, Bowers, Ben, additional, Coghill, Ben, additional, de Quadros, Bruno, additional, Cheah, Calvin, additional, Bratten, Carla, additional, Brown, Carly, additional, Moorbey, Chantelle, additional, Clisby, Charles, additional, Gordon, Charles, additional, Schramm, Chris, additional, Castle, Chris, additional, Newark, Chris, additional, Norris, Chrissie, additional, A'Court, Christine, additional, Graham, Claire, additional, Fletcher, Clare, additional, Grocott, Clare, additional, Rees, Colin, additional, Bakker, Corinne, additional, Paschalides, Costas, additional, Vickery, Craig, additional, Schembri, Damian, additional, Morris, Danielle, additional, Hagan, Daryl, additional, Cronk, David, additional, Goddard, David, additional, Graham, David, additional, Phillips, Dean, additional, Prabhu, Deeksha, additional, Kejariwal, Deepak, additional, Garg, Dhirendra, additional, Lonsdale, Diane, additional, Butterworth, Dianne, additional, Clements, Donna, additional, Bradman, Drew, additional, Blake, Duncan, additional, Mather, Elizabeth, additional, O'Farrell, Ewan, additional, Markowetz, Florian, additional, Adams, Fran, additional, Pesola, Francesca, additional, Forbes, Gareth, additional, Taylor, Gary, additional, Collins, Glenn, additional, Irvine, Gordon, additional, Fourie, Gysbert, additional, Doyle, Harriet, additional, Barnes, Heather, additional, Bowyer, Helen, additional, Whiting, Helen, additional, Beales, Ian, additional, Binnian, Ian, additional, Bremner, Ian, additional, Jennings, Ian, additional, Troiceanu, Ilona, additional, Modelell, Ines, additional, Emmerson, Ingrid, additional, Ortiz, Jacobo, additional, Lilley, Jacqueline, additional, Harvey, Jacquelyn, additional, Vicars, Jacqui, additional, Takhar, Jagjit, additional, Larcombe, James, additional, Bornschein, Jan, additional, Aldegather, Jehad, additional, Johnson, Jenny, additional, Ducker, Jill, additional, Skinner, Jo, additional, Dash, Joanne, additional, Walsh, Joanne, additional, Miralles, Jose, additional, Ridgway, Josephine, additional, Ince, Julia, additional, Kennedy, Julie, additional, Hampson, Kat, additional, Milne, Kate, additional, Ellerby, Katherine, additional, Priddis, Katherine, additional, Rainsbury, Kathy, additional, Powell, Kelly, additional, Gunner, Kerry, additional, Ragunath, Krish, additional, Knox, Kyle, additional, Baseley, Laura, additional, White, Lauren, additional, Lovat, Laurence, additional, Berney, Lee, additional, Crockett, Lindsay, additional, Murray, Lisa, additional, Westwood, Lisa, additional, Chalkley, Lisa, additional, Leggett, Loraine, additional, Dale, Louise, additional, Scovell, Louise, additional, Brooks, Lucy, additional, Saunders, Lucy, additional, Owen, Lydia, additional, Dilwershah, Maria, additional, Baldry, Marie, additional, Corcoran, Marie, additional, Roy, Marie, additional, Macedo, Mario, additional, Attah, Mark, additional, Anson, Mary-Jo, additional, Rutter, Matt, additional, Wallard, Matthew, additional, Gaw, Matthew, additional, Hunt, Matthew, additional, Lea-Hagerty, Megan, additional, Penacerrada, Melchizedek, additional, Bianchi, Michele, additional, Baker-Moffatt, Michelle, additional, Czajkowski, Michelle, additional, Sleeth, Michelle, additional, Brewer, Nick, additional, Wooding, Nick, additional, Todd, Nicky, additional, Millen, Nicola, additional, Zolle, Olga, additional, Whitehead, Orla, additional, Ojechi, Patrick, additional, Moore, Patrick, additional, Banim, Paul, additional, Spellar, Paula, additional, Bhandari, Pradeep, additional, Kant, Prashant, additional, Nixon, Rachel, additional, Russell, Rebecca, additional, Roberts, Rebekah, additional, Skule, Rene, additional, West, Richard, additional, Fox, Robin, additional, Beesley, Ruth, additional, Gibbins, Ruth, additional, Osborne, Ruth, additional, Thiagarajan, S, additional, Bastiman, Sally, additional, Warburton, Samantha, additional, Pai, Samir, additional, Leith-Russell, Sarah, additional, Utting, Sarah, additional, Watson, Sarah, additional, Wytrykowski, Sarah, additional, Singh, Satish, additional, Malhotra, Shalini, additional, Woods, Sharon, additional, Conway, Shaun, additional, Mateer, Sherrie, additional, Macrae, Shona, additional, Singh, Shruti, additional, Fourie, Simona, additional, Campbell, Siobhan, additional, Parslow-Williams, Siobhan, additional, Goel, Sonica, additional, Dellar, Stephen, additional, Jones, Stephen, additional, Knight, Steve, additional, Mackay-Thomas, Stuart, additional, Mukherjee, Stuti, additional, Allen, Sue, additional, Henry, Suzanne, additional, Evans, Tara, additional, Leighton, Theresa, additional, Bray, Tim, additional, Shackleton, Tom, additional, Santosh, Vanaja, additional, Glover, Vicki, additional, Chandraraj, Vijay, additional, Elson, Will, additional, Briggs, William, additional, Barron, Zoe, additional, and Khan, Zohrah, additional
- Published
- 2020
- Full Text
- View/download PDF
8. 634 RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL 3 (BEST3): A RANDOMISED CONTROLLED TRIAL COMPARING THE CYTOSPONGE™-TFF3 TEST WITH USUAL CARE TO IDENTIFY OESOPHAGEAL PRECANCER IN PRIMARY CARE PATIENTS WITH CHRONIC GASTROESOPHAGEAL REFLUX
- Author
-
Fitzgerald, Rebecca C., primary, Di Pietro, Massimiliano, additional, O'Donovan, Maria, additional, Muldrew, Beth, additional, Debiram-Beecham, Irene, additional, Offman, Judith, additional, Baseley, Laura, additional, Smith, Sam G., additional, Aigret, Benoit, additional, Walter, Fiona M., additional, Rubin, Greg, additional, Pesola, Francesca, additional, Gehrung, Marcel, additional, Maroni, Roberta, additional, and Sasieni, Peter, additional
- Published
- 2020
- Full Text
- View/download PDF
9. Evaluation of a minimally invasive cell sampling device coupled with assessment of Trefoil Factor 3 expression for diagnosing Barrett's esophagus: a multi-center case--control study
- Author
-
Ross-Innes, Caryn S., Debiram-Beecham, Irene, O'Donovan, Maria, Walker, Elaine, Varghese, Sibu, Lao-Sirieix, Pierre, Lovat, Laurence, Griffin, Michael, Ragunath, Krish, Haidry, Rehan, Sami, Sarmed S., Kaye, Philip, Novelli, Marco, Disep, Babett, Ostler, Richard, Aigret, Benoit, North, Bernard V., Bhandari, Pradeep, Haycock, Adam, Morris, Danielle, Attwood, Stephen, Dhar, Anjan, Rees, Colin, Rutter, Matthew D.D., Sasieni, Peter D., and Fitzgerald, Rebecca C.
- Subjects
Barrett esophagus -- Genetic aspects -- Diagnosis -- Case studies ,Gene expression -- Case studies ,Transcription factors -- Health aspects -- Case studies ,Biological sciences - Abstract
Background Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocarcinoma. Routine endoscopic screening for BE is not recommended because of the burden this would impose on the health care system. The objective of this study was to determine whether a novel approach using a minimally invasive cell sampling device, the Cytosponge, coupled with immunohistochemical staining for the biomarker Trefoil Factor 3 (TFF3), could be used to identify patients who warrant endoscopy to diagnose BE. Methods and Findings A case-control study was performed across 11 UK hospitals between July 2011 and December 2013. In total, 1,110 individuals comprising 463 controls with dyspepsia and reflux symptoms and 647 BE cases swallowed a Cytosponge prior to endoscopy. The primary outcome measures were to evaluate the safety, acceptability, and accuracy of the Cytosponge-TFF3 test compared with endoscopy and biopsy. In all, 1,042 (93.9%) patients successfully swallowed the Cytosponge, and no serious adverse events were attributed to the device. The Cytosponge was rated favorably, using a visual analogue scale, compared with endoscopy (p < 0.001), and patients who were not sedated for endoscopy were more likely to rate the Cytosponge higher than endoscopy (Mann-Whitney test, p < 0.001). The overall sensitivity of the test was 79.9% (95% CI 76.4%-83.0%), increasing to 87.2% (95% CI 83.0%-90.6%) for patients with >3 cm of circumferential BE, known to confer a higher cancer risk. The sensitivity increased to 89.7% (95% CI 82.3%-94.8%) in 107 patients who swallowed the device twice during the study course. There was no loss of sensitivity in patients with dysplasia. The specificity for diagnosing BE was 92.4% (95% CI 89.5%-94.7%). The case-control design of the study means that the results are not generalizable to a primary care population. Another limitation is that the acceptability data were limited to a single measure. Conclusions The Cytosponge-TFF3 test is safe and acceptable, and has accuracy comparable to other screening tests. This test may be a simple and inexpensive approach to identify patients with reflux symptoms who warrant endoscopy to diagnose BE., Introduction It is estimated that 5% to 15% of adults in the Western world suffer from reflux symptoms [1], and this is the commonest physician diagnosis for gastrointestinal consultations, accounting [...]
- Published
- 2015
- Full Text
- View/download PDF
10. Sa1643 - Feasibility of the Implementation of Cytosponge as a Triage Test for Reflux Symptoms in Primary Care: Barrett's Esophagus Screening Trial 3 (Best3)
- Author
-
Wilson, Ashley, primary, -Beecham, Irene Debiram, additional, Bowers, Ben, additional, Muldrew, Beth, additional, Aigret, Benoit, additional, O'Donovan, Maria, additional, Tripathi, Monika, additional, Offman, Judith, additional, Smith, Sam, additional, Jackson, Chris, additional, Pesola, Francesca, additional, Kaimi, Irene, additional, Haynes, Beverley, additional, Walter, Fiona, additional, Rubin, Greg, additional, Morris, Stephen, additional, Sasieni, Peter, additional, and Fitzgerald, Rebecca C., additional
- Published
- 2018
- Full Text
- View/download PDF
11. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial
- Author
-
Forbes, John F, Sestak, Ivana, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael, Holcombe, Chris, Coleman, Robert E, Jones, Louise, Ellis, Ian, Cuzick, Jack, Sainsbury, Richard, Garber, Judy, Warwick, Jane, Buchanan, Mary, Buser, Katharina, Cawthorn, Simon, Coleman, Robert, Dowsett, Mitch, Eastell, Richard, Ejlertsen, Bent, Forbes, John, Kahan, Zsuzsanna, Baclesse, François, Mansel, Robert, Palva, Tiina, Rydén, Lisa, Stuart, Mary, Vaz, Fatima, Marsiglia, Hugo, Benyoucef, Ahmed, Berton-Rigaud, Dominique, Loustalot, Catherine, Serin, Daniel, Kerbrat, Pierre, Eymard, Jean-Christophe, Giard-Lefevre, Sylvia, Bonichon-Lamichhane, Nathalie, Monnier, Alain, Tubiana-Mathieu, Nicole, Piot, Gilles, de Lara, Christine Tunon, Bernard, Olivier, Simon-Swirski, Hélène, Gladieff, Laurence, Regaud, I Claudius, Fouchet-Goudier, Marie-Joseph, Dohollou, Nadine, Aquitaine, Nord, Elgard-Maitre, Anne-Marie, Bergerat, Jean-Pierre, Petit, Thierry, Marti, Adina, Toussaint, Caroline, Del Piano, Francesco, Ibrahim, Mahmoud, Fric, Danièle, Hönig, Arnd, Müller, Volkmar, Marmé, Frederik, Rautenberg, Beate, Schmidt, Marcus, Hanusch, Claus, Paepke, Stefan, Kaltenecker, Gabriele, Lemster, Sabine, Tio, Joke, Reimer, Toralf, Schnappauf, Benjamin, Baumann, Klaus, Schrader, Iris, Mundhenke, Christoph, Liedtke, Cornelia, Meinerz, Wolfgang, Thomssen, Christoph, Christl, Klaus, Hitschold, Thomas, Goerke, Kay, Kast, Karin, Runnebaum, Ingo, Lindner, Christoph, Scheidel, Peter, Herwig, Uwe, Bangemann, Nikola, Sommer, Harald, Göhring, Kornelia, Tulusan, Augustinus, Stauß, Eva, Köhler, Günter, Zahm, Dirk, Augustin, Doris, Hocke, Andrea, Neunhöffer, Tanja, Schmatloch, Sabine, Heinrich, Georg, Groß, Sabine, Breitbach, G P, Scharl, Anton, Klare, Peter, Stefek, Andrea, Hoffmann, Gerald, Martignoni, Franca, Weiss, Erich, Emons, Günter, Tesch, Hans-Christian, Beckmann, Matthias, Schmutzler, Rita, Schütte, Martin, Aktas, Bahriye, Hille-Betz, Ursula, Deryal, Mustafa, Dan Costa, Serban, Blümel, Beate, Göhring, Uwe-Jochen, Kleine-Tebbe, Anke, Schumacher, Claudia, Jasmin, Pourfard, Christoph, Uleer, Kullmer, Uwe, Krabisch, Petra, Gätje, Regine, Schwenzer, Thomas, Hindenburg, Hans-Joachim, Rempen, Andreas, Höffkes, Heinz-Gert, Stickeler, Elmar, Reffert, Christian, Seitz, Stephan, Splitt, Gerd, Böhne, Petra, Gnauert, Karsten, Strittmatter, Hans-Joachim, Baake, Gerold, Rezai, Mahdi, Noesselt, Thomas, Köhne, C-H, Hanf, Volker, Strumberg, Dirk, Dall, Peter, Schleicher, Peter, Schleicher, Bernd, Beldermann, Frank, Berghorn, Michael, Baerens, Dirk-Thoralf, Kolberg, Hans-Christian, Bauer, Lelia, Brucker, Cosima, Steck, Thomas, Boyle, Frances, Chaudhuri, Anupam, Wagga, Wagga, Moylan, Eugene, Donovan, Jenny, Della-Fiorentina, Stephen, Abdi, Ehtesham, Marx, Gavin, Beadle, Geoffrey, Donovan, Michael, Bennett, Ian, Gill, Peter Grantley, Baker, Caroline, Masters, Richard, Blum, Robert, Collins, John, Law, Michael, Hart, Stewart, Kannourakis, George, Snyder, Raymond, Joseph, David, McCrystal, Michael, Campbell, Ian, Jakesz, Raimund, Selim, Ursula, Singer, Christian, Heck, Dietmar, Greil, Richard, Ramoni, Angela, Bjelic-Radisic, Vesna, Reichenauer, Arno, Horvath, Wilfried, Thaler, Josef, Fridrik, Michael, Keckstein, Joerg, Jan, Lamote, L'Hermitte, Marc, Roelstrate, Heidi, Dirix, Luc, Bambust, Inneke, Seret, Monique, Liebens, Fabienne, Maerevoet, Maria, D'Hondt, Lionel, Berliere, Martine, Nogaret, Jean-Marie, Simon, Phillipe, O'Hanlon, Deirdre, Redmond, Henry Paul, Hill, Arnold, Evoy, Denis, Kerin, Michael, Gupta, Rajnish, Martin, Michael J, Fritis, Marcela, Schwartz, Ricardo, Yañez, Maria Loreto, Peralta, Octavio, Graiff, Claudio, Artioli, Fabrizio, Generali, Daniele, Orzalesi, Lorenzo, Visini, Marilena, Michiara, Maria, Pavesi, Lorenzo, Ravaioli, Alberto, Porpiglia, Mauro, Puglisi, Fabio, Pinotti, Graziella, Brincat, Stephen, Buser, Katharina S, Rabaglio, Manuela, Rauch, Daniel, Chappuis, Pierre O, Zaman, Khalil, Bucher, Susanne, Bolliger, Barbara, Pagani, Olivia, Falck, Anna-Karin, Kaij, Jakob, Margolin, Sara, Muslumanoglum, Mahmut, Bertelli, Gianfilippo, Bramley, Maria, Bristol, James, Chandrasekharan, Sankaran, Crellin, Perric, Daoud, Raouf, Dodwell, David, Drew, Philip, Dubey, Sidharth, Evans, Abigail, Ferguson, Douglas, Gendy, Raafat, Hamed, Hisham, Harding-McKean, Claudia, Horgan, Kieran, Iqbal, Shabana, Jibril, Jibril A, Kokan, Jalal, Kneeshaw, Peter, Lansdown, Mark, Lennard, Tom, Linforth, Rick, McIntosh, Stuart, Mitra, Sankha, Neades, Glyn, Ooi, Jane Louise, Patel, Ashraf, Rayter, Zenon, Reichert, Robert, Roberts, Fiona, Roche, Nicola, Rogers, Colin, Royle, Gavin, Shah, Elizabeth, Sibbering, Mark, Skene, Anthony Iain, Smith, Simon, Sparrow, Geoffrey, Thompson, Alastair, Vaidya, Jayant, Wolstenholme, Virginia, Wood, Jeremy, Yiangou, Constantinos, Zammit, Charles, Thornton, Rochelle, Probert, Flonda, Fong, Akiko, Francis, Nicole, Gili, Manuela, Eigenberger, Rosita, Supply, Daisy, Lefever, Inge, Muller, Bettina, Zlatar, Zdenka, Feer, Petra, Gkantiragas, Ioannis, Virkki, Marjo, Everhard, Sibille, Lemonnier, Jerome, Garcia, Sara, Ghanem, Saliha, Cole, Anna, O'Hare, Debra, Cronin, Elaine, Roche, Trudi, Kennedy, Emer, Ballot, Jo, Killilea, Niamh, Jennings, Marian, Lowry, Laura, Maxwell, Moira, Burke, Margaret, Gonzaga, Aliana Guerrieri, Bollani, Giorgia, Bianchetti, Andrea, Scalvini, Anna, Cretella, Elisabetta, Pasqualini, Antonella, Gobbi, Angela, Roselli, Jenny, Lagati, Angelita, Rapacchi, Elena, Lanza, Annalisa, Pini, Emanuela, Picardo, Elisa, Maggiorotto, Furio, Sottile, Roberta, Vallini, Ilaria, Cilia, Nadia, Patel, Mital, Bamford, Linda, Robertshaw, Helen, Inman, Hayle, Hill, Naomi, Dexter, Jane, Peasgood, Emily, Batty, Imogen, Cocks, Shirley, Mistry, Raksha, Sidders, Mary, Foulstone, Emily, Garlicka, Helen, Dawe, Catherine, Elliott, Jackie, Rooke, Kathy, Morris, Christine, Lester, Yvonne, Gibson, Sian, Chittock, Jill, Skelton, Amy, Gallimore, Elizabeth, Downes, Charlotte, Billett, Lynn, Caddy, Simone, Cumming, Helen, Cowell-Smith, Sharon, Turner, Caroline, Fernando, Sunjalee, Goodwin, Sarah, Taylor, Jo-Anne, Baines, Kizzy, Downer, Susan, Pilcher, Alice, Dobson, Tracey, Osborne, Lynn, Kuenzig, Greg, Hancock, Denise, Melia, Deborah, Gullaksen, Elaine, Hartup, Susan, Henson, Amy, Gibb, Jane, Coombs, Sarah, Taylor, Caroline, Kirkby, Amy, Thomas, Issy, Makinson, Karen, Kano, Yukie, Shah, Zoheb, Hardstaff, Lisa, Townley, Barbara, Hill, Philippa, McCurrie, Marilyn, Grassby, Sue, Henderson, Pamela, Talbot, Elizabeth, Bell, Ashley, Kanani, Reshma, Johnson, Joanne, Jones, Richard, Foster, Mel, Troke, Becky, Congdon, Hilary, Pascoe, Julie, Whelan, Sian, Edwards, Jenna, Brinkworth, Elaine, Blizard, Sheila, Clarke, Alison, Stevens, Kim, Harvey, Carol, Stacey, Jill, Mitchell, Sadie, Lowry, Tracey, Buckley, Sarah, Collins, Clare, Green, Liz, Jones, Helen, Conteh, Veronica, Ducket, Tracey, Kotze, Michelle, Strider, Paula, Stouraitis, Marina, Sundberg, Jan, Babiker, Abdel, Collins, Rory, Klijn, Jan, Ralston, Stuart, Tattersall, Martin, Weller, Ian, De Sousa, Andreia, Edwards, Rob, Ferguson, Sheila, Hickman, Jane, Johnson, Damian, Haidar, Nadia, Hammond, Victoria, Heighway, Emma, Ndoutoumou, Amalia, Sahota, Navdip, White, Laura, Aigret, Benoit, Batra, Priyanka, Knox, Jill, Oke, Adedayo, Ostler, Richard, and Sasieni, Peter
- Subjects
Medicine (all) ,Medizin ,skin and connective tissue diseases - Abstract
Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS.In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had been diagnosed with locally excised, hormone-receptor-positive DCIS. Eligible women were randomly assigned in a 1:1 ratio by central computer allocation to receive 1 mg oral anastrozole or 20 mg oral tamoxifen every day for 5 years. Randomisation was stratified by major centre or hub and was done in blocks (six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation and only the trial statistician had access to treatment allocation. The primary endpoint was all recurrence, including recurrent DCIS and new contralateral tumours. All analyses were done on a modified intention-to-treat basis (in all women who were randomised and did not revoke consent for their data to be included) and proportional hazard models were used to compute hazard ratios and corresponding confidence intervals. This trial is registered at the ISRCTN registry, number ISRCTN37546358.Between March 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries and randomly assigned them to receive anastrozole (1449 analysed) or tamoxifen (1489 analysed). Median follow-up was 7·2 years (IQR 5·6-8·9), and 144 breast cancer recurrences were recorded. We noted no statistically significant difference in overall recurrence (67 recurrences for anastrozole vs 77 for tamoxifen; HR 0·89 [95% CI 0·64-1·23]). The non-inferiority of anastrozole was established (upper 95% CI
- Published
- 2016
12. Asymmetric Synthesis of 1-Aza-4-deoxypicropodophyllotoxin
- Author
-
De Borggraeve, Wim, primary, Aigret, Benoit, additional, Jacobs, Jeroen, additional, and Van Meervelt, Luc, additional
- Published
- 2013
- Full Text
- View/download PDF
13. Asymmetric Synthesis of 1-Aza-4-deoxypicropodophyllotoxin.
- Author
-
Aigret, Benoit M., Jacobs, Jeroen, Van Meervelt, Luc, and De Borggraeve, Wim M.
- Subjects
- *
PODOPHYLLOTOXIN , *MANNICH reaction , *CHEMICAL reactions , *ASYMMETRY (Chemistry) , *ORGANIC synthesis - Abstract
In our search for new easily accessible analogues based on the natural product podophyllotoxin, we synthesized 1-aza-4-deoxypicropodophyllotoxin in good overall yield and excellent enantioselectivity. The synthesis was centered around a direct asymmetric Mannich reaction using D-proline as the key step for introduction of the chiral centres. Our synthesis of 1-aza-4-deoxypodophyllotoxin was hindered through the increased instability towards epimerization of the C2 position. We did, however, synthesized a new scaffold based on the opened lactone analogue. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation.
- Author
-
Rake C, Gilham C, Bukasa L, Ostler R, Newton M, Peto Wild J, Aigret B, Hill M, Gillie O, Nazareth I, Sasieni P, Martineau A, and Peto J
- Subjects
- Aged, Aged, 80 and over, Double-Blind Method, Feasibility Studies, Female, Humans, Male, Surveys and Questionnaires, United Kingdom, Dietary Supplements, General Practitioners, Mortality, Patient Compliance, Vitamin D administration & dosage
- Abstract
Background: Randomised controlled trials demonstrating improved longevity are needed to justify high-dose vitamin D supplementation for older populations., Objectives: To demonstrate the feasibility of a large trial ( n ≈ 20,000) of high-dose vitamin D in people aged 65-84 years through general practitioner (GP) practices, and to cluster randomise participating practices between open-label and double-blind randomisation to compare effects on recruitment, compliance and contamination., Design: Twenty GP practices were randomised in matched pairs between open-label and double-blind allocation. Within each practice, patients were individually randomised to vitamin D or control (i.e. no treatment or placebo). Participants were invited to attend their GP practice to provide a blood sample and complete a lifestyle questionnaire at recruitment and again at 2 years. Randomisation by telephone followed receipt of a serum corrected calcium assay confirming eligibility (< 2.65 nmol/l). Treatment compliance was reported by quarterly follow-up forms sent and returned by e-mail or post (participant choice). GP visits and infections were abstracted from GP records. Hospital attendances, cancer diagnoses and deaths were ascertained by linkage to Hospital Episode Statistics and national registration through NHS Digital., Setting: GP practices in England., Participants: Recruitment opened in October 2013 and closed in January 2015. A total of 1615 registered patients aged 65-84 years were randomised: 407 to vitamin D and 421 to no treatment in open practices; 395 to vitamin D and 392 to placebo in blind practices., Interventions: There was a 24-month treatment period: 12 monthly doses (100,000 IU of vitamin D
3 or placebo as 5 ml oily solution) were posted after randomisation and at 1 year (100,000 IU per month corresponds to 3300 IU per day). Reminders were sent monthly by e-mail, text message or post., Main Outcome Measures: Recruitment, compliance, contamination and change in circulating 25-hydroxyvitamin D [25(OH)D] from baseline to 2 years., Results: Participation rates (randomised/invited) were 15.0% in open practices and 13.4% in double-blind practices ( p = 0.7). The proportion still taking study medication at 2 years was 91.2% in open practices and 89.2% in double-blind practices ( p = 0.4). The proportion of control participants taking > 400 IU vitamin D per day at 2 years was 5.0% in open practices and 4.8% in double-blind practices. Mean serum 25(OH)D concentration was 51.5 nmol/l [95% confidence interval (CI) 50.2 to 52.8 nmol/l] with 82.6% of participants < 75 nmol/l at baseline. At 2 years, this increased to 109.6 nmol/l (95% CI 107.1 to 112.1 nmol/l) with 12.0% < 75 nmol/l in those allocated to vitamin D and was unaltered at 51.8 nmol/l (95% CI 49.8 to 53.8 nmol/l) in those allocated to no vitamin D (no treatment or placebo)., Conclusions: A trial could recruit 20,000 participants aged 65-84 years through 200 GP practices over 2 years. Approximately 80% would be expected to adhere to allocated treatment (vitamin D or placebo) for 5 years. The trial could be conducted entirely by e-mail in participants aged < 80 years, but some participants aged 80-84 years would require postal follow-up. Recruitment and treatment compliance would be similar and contamination (self-administration of vitamin D) would be minimal, whether control participants are randomised openly to no treatment with no contact during the trial or randomised double-blind to placebo with monthly reminders., Trial Registration: Current Controlled Trials ISRCTN46328341 and EudraCT database 2011-003699-34., Funding: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 10. See the NIHR Journals Library website for further project information., Competing Interests: Irwin Nazareth was on the Health Technology Assessment (HTA) Commissioning Board from 2012 to July 2017. For the duration of the Vitamin D and Longevity (VIDAL) trial, Irwin Nazareth’s PRIMENT Clinical Trials Unit was funded by the National Institute for Health Research (NIHR). He was a member of the HTA Disease Prevention Panel, a member of the HTA Commissioning Sub-board (Expression of Interest) and a member of the HTA Primary Care Themed Call. Benoit Aigret reported that Queen Mary University of London received a grant from the London School of Hygiene & Tropical Medicine to develop the VIDAL online application during the conduct of the study.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.